Lexeo CEO granted RSUs and stock options

Lexeo Therapeutics CEO Townsend Richard Nolan received new equity awards on February 4, 2026.

Rhea-AI Filing Summary

Lexeo Therapeutics CEO Townsend Richard Nolan received new equity awards on February 4, 2026. He was granted 161,665 restricted stock units (RSUs), each representing one share of common stock, at no purchase price. After this grant, he beneficially owned 402,656 shares of common stock, including 290,022 RSUs.

He was also granted a stock option for 646,665 shares of common stock with a $7.27 exercise price. For the RSUs, 25% vest on February 15, 2027, with the remainder vesting in equal quarterly installments. For the option, 25% vests on February 4, 2027, with the balance vesting monthly thereafter, all subject to his continued service.

Insider Trade Summary

Grant/Award: 808,330 shares

Grant/Award 2 txns

Insider Townsend Richard Nolan

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	646,665	$0.00	$0.00
Grant/Award	Common Stock	161,665	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 646,665 contracts (Direct); Common Stock — 402,656 shares (Direct)

Footnotes (3)

1. F1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
2. F2. Includes 290,022 RSUs.
3. F3. 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Lexeo Therapeutics (LXEO) CEO receive in this Form 4?

The CEO, Townsend Richard Nolan, received 161,665 restricted stock units and a stock option for 646,665 shares of common stock. Both awards were granted on February 4, 2026, as part of his equity-based compensation package.

How do the new RSUs for Lexeo Therapeutics (LXEO) CEO vest?

The 161,665 RSUs vest over time. Twenty-five percent vest on February 15, 2027, and the remaining RSUs vest in 1/16th increments on the company’s standard quarterly vesting dates, conditioned on the CEO’s continued service.

What are the vesting terms of the new stock option reported by LXEO?

The stock option for 646,665 shares vests gradually. Twenty-five percent of the underlying shares vest and become exercisable on February 4, 2027, with the remaining shares vesting in 1/48th monthly installments, subject to the CEO’s continuous service.

What is the exercise price and expiration date of the Lexeo CEO’s new option?

The stock option has a $7.27 exercise price per share and expires on February 3, 2036. The long-dated term and time-based vesting align the CEO’s incentives with the company’s long-term share performance and retention goals.

How many Lexeo Therapeutics (LXEO) shares does the CEO beneficially own after this filing?

After the reported transactions, the CEO beneficially owns 402,656 shares of common stock. This total includes 290,022 restricted stock units that may settle into common shares as they vest over the specified schedule.

Are the reported Lexeo Therapeutics (LXEO) equity awards direct or indirect holdings?

Both the RSUs and the stock option are reported as directly held by the CEO. The filing does not reference any trusts, family entities, or other indirect ownership structures related to these specific awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		161,665(1)	A	$0	402,656(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.27	02/04/2026		A		646,665		(3)	02/03/2036	Common Stock	260,000	$0	646,665	D

Explanation of Responses:

1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.

2. Includes 290,022 RSUs.

3. 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Youjin Choi, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.